A phase 1, open label, multi-center, dose escalation study of the safety, tolerability, pharmacokinetic and pharmacodynamic properties of intravenously administered APG-1387 in patients with advanced solid tumors and lymphomas

Trial Profile

A phase 1, open label, multi-center, dose escalation study of the safety, tolerability, pharmacokinetic and pharmacodynamic properties of intravenously administered APG-1387 in patients with advanced solid tumors and lymphomas

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs APG 1387 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Jiangsu Ascentage Pharma
  • Most Recent Events

    • 15 Nov 2017 Status changed from recruiting to completed, according to an Ascentage Pharma media release.
    • 29 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top